MX2009004061A - Compuestos organicos. - Google Patents
Compuestos organicos.Info
- Publication number
- MX2009004061A MX2009004061A MX2009004061A MX2009004061A MX2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A
- Authority
- MX
- Mexico
- Prior art keywords
- organic compounds
- iap
- predict
- administering
- respond
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
Abstract
Un método para predecir cuáles pacientes responderán a un compuesto inhibidor de IAP, el cual comprende: a) administrar un compuesto inhibidor de IAP a un paciente, y b) medir los niveles de TNF-a o de IL-8.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86216106P | 2006-10-19 | 2006-10-19 | |
US86215506P | 2006-10-19 | 2006-10-19 | |
PCT/US2007/022125 WO2008057172A2 (en) | 2006-10-19 | 2007-10-17 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004061A true MX2009004061A (es) | 2009-04-27 |
Family
ID=39364966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004061A MX2009004061A (es) | 2006-10-19 | 2007-10-17 | Compuestos organicos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100316573A1 (es) |
EP (1) | EP2076778A2 (es) |
JP (1) | JP2010507096A (es) |
KR (1) | KR20090082221A (es) |
AU (1) | AU2007318220A1 (es) |
BR (1) | BRPI0717411A2 (es) |
CA (1) | CA2665838A1 (es) |
MX (1) | MX2009004061A (es) |
RU (1) | RU2009118487A (es) |
WO (1) | WO2008057172A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
JP5227805B2 (ja) | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Iap阻害剤とタキサン7の組合せ剤 |
TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
US8143426B2 (en) | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
KR20090041391A (ko) | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 iap 길항제 |
US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
US9750729B2 (en) * | 2008-05-16 | 2017-09-05 | Dana-Farber Cancer Institute, Inc. | Immunomodulation by IAP inhibitors |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
EP2478358A1 (en) * | 2009-09-18 | 2012-07-25 | Novartis AG | Biomarkers for iap inhibitor compounds |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
JP6513019B2 (ja) | 2012-05-04 | 2019-05-15 | ノバルティス アーゲー | Iapインヒビター治療のためのバイオマーカー |
GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
KR102166292B1 (ko) * | 2018-11-13 | 2020-10-15 | 국민대학교 산학협력단 | 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2553871A1 (en) * | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
RS52545B (en) * | 2004-04-07 | 2013-04-30 | Novartis Ag | INHIBITORI PROTEIN APOPTOZE (IAP) |
PE20080951A1 (es) * | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
-
2007
- 2007-10-17 CA CA002665838A patent/CA2665838A1/en not_active Abandoned
- 2007-10-17 WO PCT/US2007/022125 patent/WO2008057172A2/en active Application Filing
- 2007-10-17 US US12/446,430 patent/US20100316573A1/en not_active Abandoned
- 2007-10-17 EP EP07867238A patent/EP2076778A2/en not_active Withdrawn
- 2007-10-17 KR KR1020097009957A patent/KR20090082221A/ko not_active Application Discontinuation
- 2007-10-17 JP JP2009533355A patent/JP2010507096A/ja active Pending
- 2007-10-17 BR BRPI0717411-0A2A patent/BRPI0717411A2/pt not_active IP Right Cessation
- 2007-10-17 MX MX2009004061A patent/MX2009004061A/es not_active Application Discontinuation
- 2007-10-17 RU RU2009118487/15A patent/RU2009118487A/ru not_active Application Discontinuation
- 2007-10-17 AU AU2007318220A patent/AU2007318220A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2076778A2 (en) | 2009-07-08 |
CA2665838A1 (en) | 2008-05-15 |
US20100316573A1 (en) | 2010-12-16 |
JP2010507096A (ja) | 2010-03-04 |
WO2008057172A3 (en) | 2008-09-12 |
AU2007318220A1 (en) | 2008-05-15 |
KR20090082221A (ko) | 2009-07-29 |
WO2008057172A2 (en) | 2008-05-15 |
RU2009118487A (ru) | 2010-11-27 |
BRPI0717411A2 (pt) | 2013-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004061A (es) | Compuestos organicos. | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MX2009006481A (es) | Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona. | |
MX2010009736A (es) | Compuesto heterociclico. | |
HK1132175A1 (en) | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity | |
IN2014CN02483A (es) | ||
ATE554091T1 (de) | Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
WO2007079171A3 (en) | Treatment for hodgkin's lymphoma | |
EA200870357A1 (ru) | Производные тетрагидроизохинолина для повышения функции памяти | |
WO2008070129A3 (en) | Compositions and methods for the treatment of inflammatory disease | |
EA200801945A1 (ru) | Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы | |
DE602007010664D1 (de) | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen | |
MX2012004420A (es) | Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes. | |
HK1114350A1 (en) | An extract for preventing or treating thrombotic diseases | |
MX2011008289A (es) | Tabletas para terapia combinada. | |
NO346368B1 (no) | En fremgangsmåte for konsentrasjon av alfa-mannosidase. | |
UA107583C2 (ru) | Спироциклические нитрилы как ингибиторы протеазы | |
TW200700071A (en) | Novel use | |
MX2010005114A (es) | Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos. | |
DE602006016764D1 (de) | Medizinisches Telemetriesystem | |
EA200900691A1 (ru) | Применение ингибиторов iap для лечения острого миелоидного лейкоза | |
ZA200808669B (en) | Methods of treating, diagnosing or detecting cancer | |
CL2011002569A1 (es) | Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r. | |
MX2009005249A (es) | Compuestos organicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |